HOME >> MEDICINE >> NEWS
Generic vs. name brand medications

s introduce more new (and often more effective) drugs, which enjoy patent protection before they have to face competition from generics.

--The science demonstrating that generics are, in fact, bioequivalent to the name brands with which they compete has improved greatly. One argument opposing generics has traditionally been that they are not a true substitute, but now it is easier to tell if that is true scientifically, Kirking said.

--Significant restructuring in the pharmaceutical industry has led to cases where the same company makes a brand-name drug and its generic equivalent, or owns a subsidiary that does, while those companies that make only generics are merging and consolidating.

Kirking, who is professor and chair of the Department of Social and Administrative Sciences in U-M's College of Pharmacy and a research scientist in health management and policy at the U-M School of Public Health, said many people in the health care industries looked to generics as a quick-fix way to cut costs. For a number of reasons, that is not realistic, he said.

For example, a number of the most expensive medications are still under patent so no generics exist, and once the end of the patent draws near, clever pharmaceutical manufacturers reformulate---such as providing a 12-hour pill instead of one that works for four hours---and get a patent on the new and improved drug.

Kirking said therapeutic interchange might prove to play a bigger role in balancing the desire to reduce costs with the need to provide effective medication. Therapeutic interchange involves moving a patient from one drug to a different but related drug, as opposed to its chemical twin generic. This can be helpful both because very similar drugs sometimes have very different prices, as well as because one drug might not have a generic equivalent, but a related drug might. That could lead to first moving the patient from one brand-name medication to another, then t
'"/>

Contact: Colleen Newvine
cnewvine@umich.edu
734-647-4411
University of Michigan
10-Oct-2001


Page: 1 2 3

Related medicine news :

1. Generic drug use varies widely by state, study reveals
2. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
3. Generics slow rising cost of prescription drugs in 2003
4. First quarter prescription drug spending: Generic drugs slow upward trend
5. Study shows patch therapy may be as effective as oral medications
6. Use of potentially inappropriate medications among elderly common in some European countries
7. Low-dose aspirin and stomach ulcer medications better for heart patients with GI complications
8. Heart patients treated by non-cardiologists less likely to receive medications
9. Conference to examine effects of dietary supplements in patients taking blood thinning medications
10. Doctors must consider potentially inappropriate medications when treating elderly
11. Adults taking eplileptic medications more likely to be unemployed

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Generic name brand medications

(Date:4/23/2014)... Cancer Center researchers say clinical trials for a ... (AML) are very promising. Patients treated with CPX-351, ... daunorubicin, are showing better responses than patients treated ... , "Acute myeloid leukemia is an aggressive blood ... especially in older patients," explained Jeffrey Lancet, M.D., ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... that targets an important brain receptor has a dramatic ... relapse behavior, a University at Buffalo animal study has ... may be a novel lead compound for treating cocaine ... research was published as an online preview article in ... the compound, RO5263397, severely blunted a broad range of ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
Cached News: